Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Public ClinicalTrials.gov record NCT03786926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
Study identification
- NCT ID
- NCT03786926
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 53 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2019
- Primary completion
- Jun 25, 2024
- Completion
- Jun 25, 2024
- Last update posted
- Jun 25, 2025
2019 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Innovative Clinical Research Institute | Anaheim | California | 92801 | — |
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Clinical Research Alliance, Inc | Westbury | New York | 11590 | — |
| Levine Cancer Institute- Atrium Health | Charlotte | North Carolina | 28204 | — |
| Baylor Scott and White Research Institute | Dallas | Texas | 75246 | — |
| Renovatio Clinical | Houston | Texas | 77339 | — |
| University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| Medical Oncology Associates, P.S. | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03786926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2025 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03786926 live on ClinicalTrials.gov.